Formosa Pharmaceuticals Pipeline
Lead Product Candidates
For Inflammation and Pain after Cataract Surgery Treatment｜ APP13007
Through Formosa Pharma’s proprietary APNT™ nanoparticle formulation technology, our US Phase 3 completed ophthalmic asset, APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension) is expected to provide ophthalmologists and cataract patients with a compelling, rapid and sustained , and more convenient postoperative anti-inflammatory and pain relief solution.
Formosa Pharmaceuticals’ ophthalmic assets are derived from APNT™ formulation technology, which has the strong potential to address the limitations and disadvantages of currently marketed eye drops. Please refer to our Pipeline to learn more.
Formosa Pharmaceuticals’ oncology programs include ADC biosimilars as well as small-molecule NCEs. TSY-0110 is a biosimilar of Kadcyla, which is designated as the one of the second-line therapies for HER2-positive breast cancer by NCCN.
Drug Development through APNT™ Nanoparticle Formulation Technology
APNT™ has been demonstrated its applicability and benefit to formulation development in following compound classes or indications and dosage forms.
|Compound Class or Indication||Dosage forms||Benefits to the Asset|